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Abstract
Epilepsy is one of the most common neurological disorders in humans with a prevalence of 1% and a lifetime incidence of
3%. Several genes have been identified in rare autosomal dominant and severe sporadic forms of epilepsy, but the genetic
cause is unknown in the vast majority of cases. Copy number variants (CNVs) are known to play an important role in the
genetic etiology of many neurodevelopmental disorders, including intellectual disability (ID), autism, and schizophrenia.
Genome-wide studies of copy number variation in epilepsy have not been performed. We have applied whole-genome
oligonucleotide array comparative genomic hybridization to a cohort of 517 individuals with various idiopathic, non-lesional
epilepsies. We detected one or more rare genic CNVs in 8.9% of affected individuals that are not present in 2,493 controls;
five individuals had two rare CNVs. We identified CNVs in genes previously implicated in other neurodevelopmental
disorders, including two deletions in AUTS2 and one deletion in CNTNAP2. Therefore, our findings indicate that rare CNVs are
likely to contribute to a broad range of generalized and focal epilepsies. In addition, we find that 2.9% of patients carry
deletions at 15q11.2, 15q13.3, or 16p13.11, genomic hotspots previously associated with ID, autism, or schizophrenia. In
summary, our findings suggest common etiological factors for seemingly diverse diseases such as ID, autism, schizophrenia,
and epilepsy.
Citation: Mefford HC, Muhle H, Ostertag P, von Spiczak S, Buysse K, et al. (2010) Genome-Wide Copy Number Variation in Epilepsy: Novel Susceptibility Loci in
Idiopathic Generalized and Focal Epilepsies. PLoS Genet 6(5): e1000962. doi:10.1371/journal.pgen.1000962
Editor: Wayne N. Frankel, The Jackson Laboratory, United States of America
Received January 28, 2010; Accepted April 20, 2010; Published May 20, 2010
Copyright:  2010 Mefford et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work is supported, in part, by U.S. National Institutes of Health grants HD043569 to EEE, HD043376 to HCM, and NS064159 to AGB. HCM holds a
Career Award for Medical Scientists from the Burroughs Wellcome Fund. EEE is an investigator of the Howard Hughes Medical Institute. The funders had no role in
study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: hmefford@u.washington.edu
Introduction
Epilepsy is one of the most common neurological disorders in
humans with a prevalence of ,1% and a lifetime incidence of up to
3% [1]. The epilepsies present with a broad range of clinical features,
and over 50 distinct epilepsy syndromes are now recognized.
Particularly in a pediatric setting, a broad range of different epilepsy
syndromes can be distinguished. Seizure disorders can roughly be
divided into idiopathic or symptomatic epilepsies. While symptomatic
epilepsies are due to an identifiable cause such as metabolic disorders,
brain trauma or intracranial tumors, idiopathic seizure disorders
occur in the absence of identifiable causal factors and are thought to
have a strong genetic contribution.
Although it has long been observed that the idiopathic epilepsies
have a genetic component, the genetic etiology of only a small
fraction of cases can be determined. The role of copy number
variants (CNVs) in intellectual disability (ID) [2–8], autism [9–14]
and schizophrenia [15–19] has been extensively investigated. It has
become increasingly clear that, collectively, rare variants contribute
significantly to the etiology of these common diseases–following the
rare variant common disease hypothesis. We hypothesize this can be
extended to other neurological disorders and that rare CNVs
significantly contribute to the genetic etiology of epilepsy.
Recently, in a study targeted to six genomic regions, recurrent
microdeletions on chromosome 15q13.3, 16p13.11 and 15q11.2
were identified as important genetic factors predisposing to
idiopathic generalized epilepsy (IGE) [20–22]. Here, we carry
out whole-genome array comparative genomic hybridization
(CGH) in a cohort of 517 individuals with mixed types of
idiopathic epilepsy in order to discover novel copy number
changes associated with epilepsy. We find recurrent microdeletions
of 15q13.3, 16p13.11 and 15q11.2 each in ,1% of affected
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individuals, confirming previous studies [20–22]. In addition to
recurrent rearrangements at rearrangement-prone regions, we
show that, overall, 8.9% of affected individuals have one or more
rare copy number changes involving at least one gene.
Results
We performed genome-wide array CGH to detect copy number
changes in 517 patients with mixed types of epilepsy. Of these, 399
have idiopathic generalized epilepsy (IGE), 50 have benign
epilepsy with centrotemporal spikes (BECTS) and 68 have other
types of idiopathic seizure disorders (Table 1). We used a custom
microarray with high-density targeted coverage of 107 regions of
the genome flanked by large, highly homologous duplications,
termed rearrangement hotspots [23]. In addition, probes were
evenly spaced throughout the remainder of the genome with
average probe spacing of ,38 kb. Overall, we find that 46
probands (8.9%) carry one or more rare CNVs not previously
reported in the 2493 unrelated controls [24]. The rare CNVs
detected in our cohort range in size from 13 kb to 15.9 Mb
(average 1.2 Mb; median 600 kb), and the majority (69%) are
deletion events.
Rearrangements at genomic hotspots
We first evaluated rearrangement hotspots for copy number
changes. We found 20 probands (3.9%) with copy number
changes at known rearrangement hotspots including 15q13.3
deletions (n = 5), 16p13.11 deletions (n = 5), 15q11.2 BP1–BP2
deletions (n = 5), 1q21.1 deletions (n = 2), a 16p12.1 deletion
(n= 1), a 16p11.2 duplication (n= 1) and a more distal 16p11.2
deletion (n= 1) (Table 2, Figure 1). We also identified four
individuals with duplications of 15q11.2 BP1–BP2; because
duplications of this region are frequent in the general population,
we classified these duplications as polymorphic events. These
results confirm our previous studies and emphasize the importance
of deletions of 15q13.3, 16p13.11 and 15q11.2 BP1–BP2 as
frequent genetic susceptibility factors in epilepsy [20–22]. All three
regions have also been associated with ID, autism and/or
schizophrenia [15,17,25–32], as have deletions at 1q21.1
[33,34], two distinct regions of 16p11.2 [10,14,35–37] and
Author Summary
Epilepsy, a common neurological disorder characterized by
recurrent seizures, affects up to 3% of the population. In
some cases, the epilepsy has a clear cause such as an
abnormality in the brain or a head injury. However, in
many cases there is no obvious cause. Numerous studies
have shown that genetic factors are important in these
types of epilepsy, but although several epilepsy genes are
known, we can still only identify the genetic cause in a very
small fraction of cases. In order to identify new genes that
contribute to the genetic causes of epilepsy, we searched
the human genome for deletions (missing copies) and
duplications (extra copies) of genes in ,500 patients with
epilepsy that are not found in control individuals. Using
this approach, we identified several large deletions that are
important in at least 3% of epilepsy cases. Furthermore, we
found new candidate genes, some of which are also
thought to play a role in other related disorders such as
autism and intellectual disability. These genes are candi-
dates for further studies in patients with epilepsy.
Table 1. Phenotypes of probands evaluated by array CGH.
Type of epilepsy N
Hotspot CNVs
detected
Other CNVs
detected Total
IGE (n =399)
Juvenile myoclonic epilepsy (JME) 189 8‘ 9‘ 17
Absence epilepsy (AE) 94 5 5* 10
IGE with GTCS only 33 0 2 2
IGE unclassified 63 2 4 6
Benign myoclonic epilepsy of infancy 5 0 0 0
Myoclonic astatic epilepsy (MAE) 15 0 2 2
Idiopathic focal epilepsy (n =63)
BECTS 50 3 2 5
ABPE 13 0 0 0
Other (n =55)
ESES 4 0 0 0
Landau-Kleffner syndrome 3 0 0 0
Severe IGE of infancy (SIGEI) 15 1 1 2
West syndrome 4 0 2* 2
IC/NC 10 1 2* 3
Unclassified 19 0 2 2
Total 517 20 31 51
IGE, idiopathic generalized epilepsy; GTCS, generalized tonic-clonic seizures; BECTS, benign epilepsy with centrotemporal spikes; ABPE, atypical benign partial epilepsy;
ESES, electrical status epilepticus during slow-wave sleep; IC, infantile convulsions; NC, neonatal convulsions;
*indicates two events in a single individual;
‘ two individuals (EMJ071 and EMJ117) each carrying one hotspot and one non-hotspot event.
doi:10.1371/journal.pgen.1000962.t001
CNVs in Epilepsy
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Table 2. Rare copy number variants in 517 patients with epilepsy.
Case
Chromosome
Location HS
Coordinates
(build36; Mb) Size CNV Inheritance Phenotype
RefSeq
genes (n)
Possible
candidate
genes
Idopathic Generalized Epilepsies (n =399)
EMJ 049 1q21.1 Y Chr1: 145.0–145.9 900 kb Del - JME 8 GJA8
ND02006 15q11.2 Y Chr15: 20.2–20.8 600 kb Del - IAE 4 CYFIP1
ND03383 15q11.2 Y Chr15: 20.2–20.8 600 kb Del - CAE 4 CYFIP1
ND06631 15q11.2 Y Chr15: 20.2–20.8 600 kb Del Inh (P) CAE 4 CYFIP1
K004 15q11.2 Y Chr15: 20.2–20.8 600 kb Del Inh (P) IGE 4 CYFIP1
EPI 62 15q13.3 Y Chr15: 28.7–30.1 1.4 Mb Del - IAE 6 CHRNA7
EMJ 001** 15q13.3 Y Chr15: 28.7–30.1 1.4 Mb Del - JME 6 CHRNA7
EMJ 002 15q13.3 Y Chr15: 28.7–30.1 1.4 Mb Del - JME 6 CHRNA7
EMJ 020** 15q13.3 Y Chr15: 28.7–30.1 1.4 Mb Del - JME 6 CHRNA7
IA G5 15q13.3 Y Chr15: 28.7–30.1 1.4 Mb Del - IGE + ID 6 CHRNA7
EMJ 162 16p11.2 Y Chr16: 29.5–30.2 700 kb Dup - JME 30 SEZ6L2
ND3074 16p13.11 Y Chr16:15.4–16.3 900 kb Del Inh (M) CAE 6 NDE1
EPI 17 16p13.11 Y Chr16:15.4–16.3 900 kb Del - JME 6 NDE1
EMJ 071* 16p13.11 Y Chr16:15.4–16.3 900 kb Del - JME 6 NDE1
EMJ 117* 16p13.11 Y Chr16: 15.4–18.5 3.1 Mb Del - JME 7 NDE1
ND05586 1p31.1 Chr1: 72.04–72.15 111.3 kb Del Inh (P) CAE 1 NEGR1
ND05260* 4q22.2 Chr4: 94.18–94.83 646.6 kb Del Inh (M) CAE 1 GRID2
K 111 5p15.33 Chr5: 0.72–1.43 713.0 kb Dup Inh (M‘) MAE 10 NKD2, SLCA18
EP007.1 5q33.2 Chr5: 153.2–160.3 7.1 Mb Del Not in M IGE + ID 44 CYFIP2
EMJ 005 6q12 Chr6: 65.03–66.09 1.06 Mb Dup - JME 1 EYS
ND01440 7q11.22 Chr7: 69.38–69.46 78.7 kb Del - JME 1 AUTS2
K 039 7q36.1 Chr7: 151.35–151.43 85.8 kb Del Inh (P) MAE 1 GALNT11
ND03578 8q21-q22 Chr8: 83.97–97.20 15.9 Mb Dup Inh (P) JME+ID 50 many
EMJ 013 9p21.3 Chr9: 21.21–21.63 427.5 kb Del - JME 9 KLHL9
EP005.1 9q21.32 Chr9: 83.9–85.2 1.30 Mb Del Inh (M) IGE 2 RASEF
ND05260* 9q31.3 Chr9: 113.33–114.33 1.01 Mb Dup Inh (M) CAE 10
EMJ 071* 13q31.1 Chr13: 84.69–85.36 671.8 kb Del - JME 1 SLITRK6
EMJ 067 14q24.2 Chr14: 70.96–71.23 268.6 kb Del - JME 1 SIPA1L1
EPI 66 15q25.2 Chr15: 83.00–83.12 117.4 kb Dup - IAE 3 NBM
ND03244 16q23.1 Chr16: 74.49–75.27 785.8 kb Dup - GTCS only 1 CNTNAP4
EPI 52 17p11.2 Chr17: 19.92–19.94 13.3 kb Del - GTCS only 1 CYTSB
EMJ 117* 17p11.2 Chr17: 19.92–19.94 17.5 kb Del - JME 1 CYTSB
EPI 40 17q12 Chr17: 30.53–30.87 338.5 kb Del - IAE 7 UNC45
EMJ 039 18q11.2 Chr18: 19.66–20.50 840.4 kb Dup - JME 6
EMJ 069 18q11.2 Chr18: 19.66–20.50 840.4 kb Dup - JME 6
ND02416 21q21.1 Chr21: 16.21–18.81 2.59 Mb Dup Inh (M) IGE + ID 7
EPI 26 Xp22.31 ChrX: 7.78–8.39 605.5 kb Dup - IGE 4 PNPLA4
Idiopathic Focal Epilepsies (n =63)
EPI 60 1q21.1 Y Chr1: 145.0–145.9 900 kb Del - BECTS 8
K 105 16p12.1 Y Chr16: 21.8–22.3 500 kb Del - BECTS 7
EPI 21 16p13.11 Y Chr16: 15.4–16.3 900 kb Del - BECTS 6 NDE1
EPI 58 4q35.1 Chr4: 186.30–186.61 302.4 kb Dup - BECTS 8 SLC25A, SNX25
K 093 8p23.1 Chr8: 10.19–10.37 173.1 kb Del - BECTS 1 MSRA
Other (n =55)
K 047 15q11.2 Y Chr15: 20.2–20.8 600 kb Del brother‘ IC 4 CYFIP1
K 027 16p11.2 Y Chr16:28.7–28.9 200 kb Del - SIGEI 9
K 109 2q35 Chr2: 218.36–218.94 571.9 kb Dup - SIGEI 11
CNVs in Epilepsy
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16p12 [38], which were also detected in our cohort. Deletions of
16p13.11 (5/517 vs 0/2493 controls, p = 0.00014, Fisher’s exact
test), 15q13.3 (5/517 vs 0/2493, p= 0.00014) and 15q11.2 (5/517
vs. 4/2493, p = 0.010) are significantly enriched in our epilepsy
cohort and together account for 2.9% of cases.
Rare or unique deletions involving potential candidate
genes
We next focused on non-hotspot CNVs that overlap one or
more genes and are not present in the control cohort of 2493
individuals [24]. We identified 28 individuals with at least one rare
gene-containing deletion or duplication, and five individuals each
carry two rare CNVs (Table 2). Fifteen of the events we detected
involve a single gene. Two genes were altered in two patients each:
AUTS2 deletions were identified in one proband with juvenile
myoclonic epilepsy (JME) and one proband with unclassified non-
lesional epilepsy with features of atypical benign partial epilepsy
(ABPE) [39]. Deletions involving CTYSB (SPECC1) were identified
in two probands with IGE. All other single-gene CNVs were seen
only once. Seventeen events involved multiple genes, one of which
was observed in two different individuals with JME (duplication of
18q11, Table 2).
Individuals with multiple rare CNVs
We found five individuals with two rare CNVs (Figure 2). Two
patients with JME and a deletion of 16p13.11 (EMJ071 and
EMJ117) each have a second rare deletion. EMJ071 has a large
deletion on chromosome 13 that removes the SLITRK6 gene, a
member of the SLITRK gene family involved in controlling
neurite outgrowth; individual EMJ117 also has a deletion
involving the CTYSB gene. Case ND05260 (childhood absence
epilepsy, CAE) carries a 647-kb deletion within the GRID2 gene,
which encodes a glutamate receptor expressed in the cerebellum,
and a 1-Mb duplication of 9q31. Though both are maternally
inherited, neither has been reported in controls. Case EPI 51
(idiopathic West syndrome) has two apparently independent
duplications of chromosome 5q35, each containing several genes.
Finally, we identified one proband with neonatal convulsions (NC)
carrying a deletion within the CNTNAP2 gene that spans exons 2–
4 as well as a 370-kb deletion of 17p13 involving 7 genes.
DNA from one of more family members was available for
analysis in 14 cases. Inheritance, if determined, is shown in
Table 2. In twelve cases, we determined that one or both CNVs in
the proband were inherited; in three cases the transmitting parent
is also affected. In one case (EP007.1), the CNV was not found in
the mother, but the father was unavailable. In another case
(K047), parents were unavailable, but a brother was found to carry
the same CNV suggesting one of the parents carries the same
CNV.
Discussion
In this study, we performed whole-genome array CGH in a
series of 517 individuals with a presenting diagnosis of idiopathic
epilepsy in order to discover novel copy number changes
associated with epilepsy. While our previous studies were targeted
to specific genomic regions in probands with IGE [21,22], here we
present data from whole-genome analysis on probands with IGE
and extend our analysis to other idiopathic epilepsy syndromes. In
total, we identified 46 individuals (8.9%) with 51 rearrangements
that may be pathogenic as they were not found in controls or were
significantly enriched in our epilepsy cohort.
Hotspot rearrangements
Rearrangements at several genomic hotspots have been
associated with a range of neurocognitive disorders. In our cohort
of 517 probands with epilepsy, we find deletions at 15q13.3,
16p13.11 and 15q11.2 in 2.9% of our cases. Interestingly, all of the
deletions of 15q13.3 (n = 5) and 4/5 deletions at 16p13.11 and
15q11.2 were in probands with IGE, accounting for 3.3% of the
patients with IGE in our cohort confirming our previous findings.
While it is possible that deletions of 15q13.3 are also predisposing
to non-IGE epilepsy syndromes, we did not find this to be the case
in our series (n = 118). Additional large cohorts of patients with
focal epilepsy or epileptic encephalopathy will be required to
determine whether these deletions also play a significant role in
other subtypes of epilepsy.
Deletions of 16p13.11 have previously been associated with
intellectual disability +/2 congenital anomalies in one study [26].
Three of four probands with 16p13.11 deletions in that series had
epilepsy; two further fetal cases had brain abnormalities. The
findings in this cohort and one previous study of IGE [20] suggest
that deletions of 16p13.11 are more frequent in epilepsy (0.5–1%
of cases) than in other phenotypes including ID and autism
[26,27,32], and may be as frequent as 15q13.3 deletions in
Table 2. Cont.
Case
Chromosome
Location HS
Coordinates
(build36; Mb) Size CNV Inheritance Phenotype
RefSeq
genes (n)
Possible
candidate
genes
EPI 51* 5q35.1 Chr5: 167.62–167.89 268.7 kb Dup - West 4 WWC1
EPI 51* 5q35.1 Chr5: 169.43–169.64 230.0 kb Dup - West 4 DOCK2, FOXI1
K 054 7q11.22 Chr7: 69.38–69.42 38.3 kb Del - Unclassified 1 AUTS2
K034* 7q35 Chr7:146.06–146.36 304.4 kb Del Inh (P‘) NC 1 CNTNAP2
ND08273 15q13.3-q14 Chr15: 30.66–32.44 1.78 Mb Dup Inh (M) Unclassified 15
K034* 17p13.1 Chr17:10.36–10.72 370 kb Del Inh (P‘) NC 7 MYH1-3; SCO
HS, hotspot region; Del, deletion; Dup, duplication; Inh, inherited; M, maternal; P, paternal;
‘affected; -, parents unavailable; JME, juvenile myoclonic epilepsy; IAE, idiopathic absence epilepsy; CAE childhood absence epilepsy; IGE, idiopathic generalized
epilepsy; GTCS, generalized tonic clonic seizures only; ID, intellectual disability; BECTS, benign epilepsy with centrotemporal spikes; IC, infantile convulsions; SIGEI,
several idiopathic generalized epilepsy of infancy; NC, neonatal convulsions;
*two CNVs detected in same individual;
**15q13 deletions previously detected by MLPA [60].
doi:10.1371/journal.pgen.1000962.t002
CNVs in Epilepsy
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individuals with IGE. Deletions and duplications of this region
have also been reported in schizophrenia, though the associations
have not been statistically significant [16,29].
Deletions of 15q13.3, detected in five individuals with IGE in
our series, have been associated with a wide range of phenotypes
including ID, autism, epilepsy and schizophrenia [15,17,20–
22,25,28,30,31,40]. The gene within the 15q13.3 region that is
most likely responsible for the epilepsy phenotype is CHRNA7, a
subunit of the nicotinic acetylcholine receptor. At least two
small studies have failed to identify causal point mutations in the
CHRNA7 gene in autosomal dominant nocturnal frontal lobe
epilepsy [41] and JME [42], but additional studies should be
performed to further evaluate affected individuals for mutations.
A recent publication identifying atypical rearrangements with
exclusive deletions of CHRNA7 further emphasizes the impor-
tance of CHRNA7 as the main candidate gene in this region
[43].
Compared to the above structural genomic variants, copy
number variation at 15q11.2 between breakpoints BP1 and BP2 of
the Prader-Willi and Angelman syndrome region is more common
in the general population with the BP1–BP2 deletion present in
0.2% of unaffected individuals. Despite this, deletions between
BP1 and BP2 have now been reported as enriched in patients with
schizophrenia [16,17], ID [27] and epilepsy [20]. Furthermore,
there is evidence that patients with Prader-Willi or Angelman
syndrome who have deletions including BP1–BP2 are more
severely affected [44–46]. In this study, we also find enrichment of
deletions at this locus in affected individuals. Together, these
studies suggest that deletion of the 15q11.2 BP1–BP2 region
confers susceptibility to a wide range of neuropsychiatric
conditions, albeit with incomplete penetrance.
Two patients in our series, one each with JME and BECTS,
have deletions of 1q21.1, which have been previously associated
with a wide range of phenotypes, including intellectually disability
and developmental delay [33,34], schizophrenia [15,17,18],
congenital heart disease [47,48] and cataracts [34,49]. In two
large studies of patients who present primarily with cognitive or
developmental delay, 5/42 (11.9%) patients also had seizures
[33,34]; 1 of 10 patients with schizophrenia and a 1q21.1 deletion
also had epilepsy [15]. Identifying 1q21.1 microdeletions in
patients with idiopathic generalized and idiopathic focal epilepsies
suggests that variation at this locus predisposes to a broad range of
seizure disorders crossing traditional diagnostic boundaries.
In addition, we identified one patient (EMJ162) with JME and a
duplication of 16p11.2 (chr16: 29.5–30.2 Mb), which has been
associated with autism, developmental delay and schizophrenia
[10–12,14,27,35,37]. Finally, we identified one individual with
severe idiopathic generalized epilepsy of infancy (SIGEI) (K027)
with a more distal deletion of 16p11.2 (chr16: 27.7–28.9 Mb),
recently associated with severe early-onset obesity and ID [36],
and one patient with BECTS (K105) and a deletion of 16p12.1
(chr16: 20.2–20.8 Mb), also associated with ID and other
neurodevelopmental defects [38]. Thus, our data adds to the
phenotypic spectrum associated with rearrangements at several
genomic hotspot regions. In particular, we identify hotspot
deletions in two patients with BECTS. Gene identification in
BECTS, despite representing the most common focal epilepsy
syndrome of childhood, has been elusive so far. Here, we suggest
that some recurrent hotspot deletions might predispose to both
idiopathic generalized and focal epilepsies.
Non-hotspot rearrangements
We detected 18 deletions and 16 duplications that are not
associated with rearrangement hotspots. Fifteen events involve a
single gene; of these, 12 are deletions. Although all of the CNVs
reported here are not found in our control set of 2493 individuals,
it is possible that some are rare but benign CNVs. However, many
of the CNVs we identified contain one of more plausible candidate
genes for epilepsy (Table 2).
We identified a deletion of exons 2–4 in the CNTNAP2 gene in a
proband with neonatal seizures. CNTNAP2 has been identified as a
candidate gene for autism [50–52], and heterozygous deletions
involving the gene were reported in three patients with
schizophrenia and autism [53]. The deletion is predicted to cause
an in-frame deletion of 153 amino acids in the resulting protein.
The same patient has a 370-kb deletion of 17p13 that deletes seven
genes and has not been seen in our control cohort. We also
identified a patient with a duplication encompassing a related
gene, CNTNAP4. Finally, two individuals in our cohort have
overlapping deletions within AUTS2. This gene is disrupted by de
novo balanced translocations in three unrelated individuals with
mental retardation [54] and a pair of twins with autism and mental
retardation [55], suggesting a role for AUTS2 in normal cognitive
development. The two deletions we detected are intragenic and
overlapping.
CNVs in epilepsy subtypes
Previous studies of CNVs in epilepsy have focused on probands
with IGE. It is known from studies of families with autosomal
dominant epilepsy that a wide range of seizure types can be caused
by the same single-gene mutation. For example, Dravet syndrome,
a severe early-onset disorder associated with poor cognitive
outcome, and the milder generalized epilepsy with febrile seizures
plus (GEFS+) syndrome are both caused by mutations in the
SCN1A gene [56–58]. Therefore, we included probands with
common idiopathic focal epilepsies and non-lesional, idiopathic
epilepsies. Some of our probands were diagnosed with specific
epilepsy syndromes, including myoclonic astatic epilepsy (Doose
Syndrome), atypical benign partial epilepsy [39], Landau-Kleffner
syndrome, idiopathic West syndrome, severe idiopathic general-
ized epilepsy of infancy [59] and benign neonatal or infantile
seizures. These particular epilepsy syndromes are usually associ-
ated with normal MRI results. We find that 6.6% of probands with
IGE and 7.9% of those with idiopathic focal epilepsy harbor rare
CNVs that may underlie their epilepsy phenotype. Notably, 12.7%
of patients with other, often more severe forms of epilepsy in our
series carry one or more rare CNVs. In our series, the vast
majority of patients with deletions of 15q13.3, 16p13.11 and
15q11.2 BP1–BP2 were in the IGE cohort, accounting for 3.3% of
cases. In the non-IGE patients, a deletion of 15q11.2 was found in
a single patient with infantile seizures and a deletion of 16p13.11
was found in one patient with BECTS, suggesting that deletions at
Figure 1. Deletions and duplications at genomic rearrangement hotspots in 20 probands. Array CGH results are depicted for (A) 15q13.3,
chr15: 28.0–31.0 Mb, (B) 16p13.11, chr16: 14.5–18.5 Mb, (C) 15q11.2, chr15: 20.0–20.9 Mb, (D) 1q21.1, chr1: 144.0–147.5 Mb, (E) 16p12.1, chr16: 21.6–
22.6 Mb, (F) 16p11.2, chr16:28.6–29.1 Mb, and (G) 16p11.2, chr16: 29.0–30.3 Mb. For each individual, deviations of probe log2 ratios from 0 are
depicted by gray and black lines. Those exceeding a threshold of 1.5 s.d. from the mean probe ratio are colored green and red to represent relative
gains and losses, respectively. Segmental duplications of increasing similarity (90–98%, 98–99%, and .99%) are represented by gray, yellow, and
orange bars, respectively. RefSeq genes are depicted in blue.
doi:10.1371/journal.pgen.1000962.g001
CNVs in Epilepsy
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these three genomic hotspots confer greater risk for IGE than
other types of epilepsy.
In summary, we find that 46/517 probands (8.9%) with various
forms of idiopathic epilepsy carry one or more rare CNVs that may
predispose to seizures, a frequency similar to that in studies of patients
who present with other neurocognitive phenotypes, including ID,
autism and schizophrenia. Furthermore, we identified CNVs
involving genes and genomic regions previously identified in patients
with the neurocognitive phenotypes listed above, suggesting common
genetic etiological factors for these disorders. Our data suggest that
rare CNVs are important in many subtypes of idiopathic epilepsies,
including idiopathic generalized and idiopathic focal epilepsies as well
as specific idiopathic, non-lesional epilepsy syndromes. The genomic
regions and genes identified in this study are potential novel candidate
genes for epilepsy.
Materials and Methods
Ethics statement
Patients were collected at five centers after appropriate human
subjects approval and informed consent at each site.
Patient cohorts
Patients were collected at five centers: (1) 140 probands with a
primary diagnosis of JME, CAE, absence epilepsy, IGE or idiopathic
epilepsy were selected from the NINDS repository (http://ccr.coriell.
org/ninds); (2) 160 patients are probands with a primary diagnosis of
JME from Switzerland. Patients from cohorts (1) and (2) were
previously analyzed usingMLPA for the CHRNA7 gene [60], and two
probands (EMJ001 and EMJ020) were determined to have 15q13.3
microdeletions by that method; they were not previously analyzed for
any other copy number changes. (3) 186 German patients came from
two cohorts: 76 patients from a population-based cohort from
Northern Germany (POPGEN cohort) and 110 patients with
childhood-onset epilepsy collected at the University of Kiel. Finally,
41 patients with various idiopathic generalized epilepsies collected at
(4) the University of Iowa and (5) at Washington University, St. Louis.
DNA from the NINDS repository was derived from cell lines; DNA
from all other cohorts was directly from blood. Patients were
diagnosed according to the widely used 1989 ILAE classification [61].
In addition, several pediatric patients were diagnosed with specific
syndromes not yet recognized in the ILAE classification (Table 1).
Patients with non-lesional, idiopathic epilepsies in which diagnostic
criteria of the recent ILAE classification for particular epilepsy
syndromes were not met were labeled as ‘‘unclassified’’.
Array comparative genomic hybridization (CGH)
Array CGH was performed using either custom or commer-
cially available oligonucleotide arrays containing 135,000 isother-
mal probes (Roche NimbleGen, Inc.). Customized arrays (459
samples) were designed with higher density probe coverage in
known rearrangement hotspot regions (average probe spacing
2.5 kb) with lower density whole-genome backbone coverage
(average probe spacing 38 kb). A subset of samples (n = 62) was
analyzed using a commercially available whole-genome array
(Roche NimbleGen 126135 k whole-genome tiling array) with
average probe spacing throughout the genome of 21 kb.
Data analysis
Data were analyzed according to manufacturer’s instructions using
NimbleScan software to generate normalized log2 fluorescence
intensity ratios. Then, for each sample, normalized log intensity
ratios are transformed into z-scores using the chromosome-specific
mean and standard deviation. Z-scores are subsequently used to
classify probes as ‘‘increased’’, ‘‘normal’’ and ‘‘decreased’’ copy-
number using a three-state Hidden Markov Model (HMM). The
HMM was implemented using HMMSeg [62], which assumes
Gaussian emission probabilities. The ‘‘increased’’ and ‘‘decreased’’
states are defined to have the same standard deviation as the
‘‘normal’’ state but with mean z-score two standard deviations above
and below the mean, respectively. Probe-by-probe HMM state
assignments are merged into segments according to the following
criteria: consecutive probes of the same state less than 50 kb apart are
merged, and if two segments of the same state are separated by an
intervening sequence of #5 probes and #10 kb, both segments and
intervening sequence are called as a single variant. CNV calls are
filtered to eliminate (i) events containing ,5 probes, (ii) CNVs with
.50% overlap in a series of 2493 control individuals [24] and (iii)
events that had no overlap with RefSeq genes. In addition, when
comparing CNV calls to control CNVs, we eliminated calls for which
there was insufficient probe coverage (,5 probes) in the control data
to identify the same or similar CNV. Filtered copy number changes
are also visually inspected in a genome browser.
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